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Highlights  
• Available PD models range from classical cell lines to 3D midbrain organoids.  
• A fully reliable in vitro model for the understanding of PD etiology is still lacking. 
• Human-derived models open new routes for PD modeling and drug screening. 
 
Abstract  
Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized by 
loss of dopaminergic (DAergic) neurons in the substantia nigra that contributes to the main motor 
symptoms of the disease. At present, even if several advancements have been done in the last decades, 
the molecular and cellular mechanisms involved in the pathogenesis are far to be fully understood. 
Accordingly, the establishment of reliable in vitro experimental models to investigate the early events 
of the pathogenesis represents a key issue in the field. However, to mimic and reproduce in vitro the 
complex neuronal circuitry involved in PD-associated degeneration of DAergic neurons still remains 
a highly challenging issue. Here we will review the in vitro PD models used in the last 25 years of 
research, ranging from cell lines, primary rat or mice neuronal cultures to the more recent use of 
human induced pluripotent stem cells (hiPSCs) and, finally, the development of 3D midbrain 
organoids.  
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1.1 Introduction 
The use of in vitro models allows the analysis of molecular and cellular pathogenic events as well as 
drug screening in fully controlled environment conditions. However, taking into consideration that 
Parkinson’s Disease (PD) is a very complex brain disorder that involves several neuronal circuitries 
and brain areas, it remains really challenging to reproduce in vitro in a cell culture the complexity of 
these aspects. In the last three decades a vast variety of cell culture systems, ranging from cell lines 
to the more recent 3D organoids, have been used as in vitro models to study PD pathogenesis as well 
as to test possible neuroprotective agents.   
1.2 Cell lines 
Established cell-lines (either differentiated or not) are immortalized cells derived from a multicellular 
organism. This type of cell lines has several advantages (Lopes et al., 2017): 
1. highly proliferative; 
2. high reproducibility, 
3. can be easily genetically manipulated; 
4. some of them, present all the DAergic machinery, for example enzymes for DA metabolism and 
synaptogenesis (Lopes et al., 2017); 
5. many of them have human origins and therefore human genetic background. 
 
However, the use of these models is limited by relevant disadvantages: 
1. they often require further differentiation steps to have the morphological and/or physiological 
characteristics of DAergic neurons; 
2. they have oncogenic origin; therefore, their main feature is the high proliferation which is in clear 
contrast with neuronal feature (Herrup and Young 2007; Lopes et al., 2017). 
 
The pathological hallmarks of PD can be reproduced in these cultures either genetically, through the 
overexpression or silencing of PD-related genes (SNCA, Parkin, PINK1, LRKK2, GBA), or 
chemically, through the use of neurotoxins (such as 6-OHDA, MPP+, rotenone), which alters many 
cellular processes. Therefore, enabling to highlight the different molecular pathways altered in PD 
complex pathophysiology, genetic models allow to reproduce a condition that is more similar to the 
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in vivo one. Overall, this type of cell lines should be used mainly for evaluating apoptosis, 
mitochondrial and gene dysfunction, oxidative stress, screening of potential drugs and their relative 
neuroprotective properties. In this review, we will focus on the following immortalized cell lines: 
SH-SY5Y, PC12, LUMHES, N2a, N27, MN9D. 
 
1.2.1 SH-SY5Y cell line 
SH-SY5Y are a subclone of the SK-N-SH neuroblastoma cells, obtained in 1978 starting from a 4-
year-old girl bone marrow biopsy (Biedler et al., 1978). The original cell line SK-N-SH presents two 
phenotypes characterized by different morphological and biochemical features: one is defined as N-
type (neuroblastic) and the other is called S-type (epithelial, adherent) (Encinas et al., 2000; 
Kovalevich and Langford, 2013); both can be differentiated in neurons (Ross et al., 1983). SH-SY5Y 
cells have a neuroblastoma-like morphology characterized by round cell bodies and short processes 
(Påhlman et al., 1984). As undifferentiated cells, they are not DAergic cells, having instead a 
catecholaminergic phenotype, as they can synthesize both DA and noradrenaline (NA) (Xicoy et al., 
2017). SH-SY5Y cells present, when not differentiated, activity of DA-β-hydroxylase (Biedler et al., 
1978) and of tyrosine hydroxylase (Ross and Biedler, 1985), a basal release of noradrenaline (NA) 
(Påhlman et al.,1984; Xicoy et al., 2017), and expression of DA transporter (DAT) (Cheung et al., 
2009). Furthermore, alongside the good activity of the DAT, on the other hand, they are characterized 
by a low activity of the vesicular monoamine transporter type 2 (VMAT2). Accordingly, the 
concentration of endogenous DA (normally very low) can be regulated through external 
administration in the culture medium (Alberio et al., 2010, 2012). Additionally, although these cells 
present a complete DAergic apparatus, they do not exhibit neuronal features and are highly 
proliferative, as their oncogenic origin suggests. Moreover, these cells have a low expression of 
neuronal markers because they are in the early phases of neuronal differentiation (Lopes et al., 2017). 
To obtain cells with a neuronal phenotype, a differentiation protocol is needed. Several methods have 
been used: the most common is based on the use of retinoic acid (RA), with varying concentrations 
and incubation times (Xicoy et al., 2017). Another differentiation protocol involves the use of 12-O-
Tetradecanoyllphorbol-13-acetate (TPA), with or without RA. This method is more effective to 
obtain a DAergic cell phenotype (Xicoy et al., 2017). In this regard, in 2004 Presgraves and 
colleagues, starting from the method used by Pennybacker et al., developed the differentiation 
protocol through RA and TPA, to obtain dopaminergic cells from SMS-KCNR neuroblastoma cells. 
In fact, RA/TPA treated cells have a dopaminergic phenotype with higher levels of expression of TH 
and DAT, as well as dopaminergic D2 and D3 receptors. Therefore, this cell-line could be a useful 
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tool in the study of the neuroprotection of dopamine agonists against MPP+ and DA-induced toxicity. 
[Pennypacker et al., 1989; Presgraves et al., 2004]. 
However, other studies show that this method leads to a formation of a heterogeneous neuronal 
population, with an increase of NA neurons (Xicoy et al., 2017, Påhlman et al., 1984). Another 
protocol, instead, promotes the use of brain-derived neurotrophic factor (BDNF) together with RA. 
This method consists in the induction of a low proliferative and homogeneous neuronal population 
(Encinas et al., 2000; Xicoy et al., 2017). The differentiation with RA and BDNF seems to induce a 
reduced degree of proliferation, a typically neuronal morphology with the development of neurites, 
an increase in the expression of neuronal (NeuN) and DAergic (TH) markers and greater sensitivity 
to 6-OHDA (Lopes et al., 2010, 2017).  
As previously mentioned, SH-SY5Y can undergo both genetic and chemical modifications to mimic 
the pathological features of PD (Wu et al., 2018; Li N et al. 2019; Wang et al., 2019; Ferlazzo et al., 
2019). Even if many cellular processes can be investigated by using this cell line (i.e. drug screening, 
oxidative stress, apoptosis, mitochondrial alteration, autophagy) (Li et al., 2019; Limboonreung et 
al., 2019; Lualdi et al., 2019; Md et al., 2019; Ramalingam et al. 2019; Ju et al., 2019), it cannot be 
used for electrophysiological studies or assessment of neurochemical alterations (Xicoy et al., 2017). 
Regarding their electrophysiological properties, different studies have shown variable responses 
between individual cells although exposed to the same experimental stimuli. These observations 
suggest that these cells are made up of non-uniform subpopulations, with a different expression and 
density of membrane channels (Tosetti et al., 1998; Santillo et al., 2014). SH-SY5Y cells have also 
been used in a-synuclein studies, in particular to better understand its role in the various cellular 
mechanisms altered in PD, such as autophagy-lysosomal pathways, mitochondrial functions and the 
role of dopamine agonists (Bellucci et al., 2008; Vogiatzi et al., 2008; Bellucci et al., 2011; Diogenes 
et al., 2012; Fares et al., 2014; Mahul-Mellier et al., 2014; Zaltieri et al., 2015).  
 
1.2.2 LUHMES line 
The LUHMES (Lund Human Mesencephalic cells) lines are a subclone of human mesencephalic cell 
lines MESC 2.10 that were isolated from the ventral mesencephalic brain region of an 8-week-old 
fetus and were immortalized by introducing a tetracycline-controlled, v-myc-gene (TET-off) 
(Lotharius et al., 2005; Zhang et al., 2014; Lopes et al., 2017). Unlike SH-SY5Y, this cell line shows 
specific DAergic markers and typical neuronal morphology with long neurites even if only after 
differentiation with tetracycline, cyclic AMP (cAMP) and glial derived neurotrophic factor (GDNF) 
(Lotharius et al., 2005; Scholz et al., 2011, Zhang et al., 2014). Once differentiated, these cells have 
spontaneous electrical properties, express DAergic factors such as TH, DAT, VMAT and D2 
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receptors, are able to release DA and acquire the morphology of primary neurons (Scholz et al., 2011; 
Zhang et al., 2014; Lopes et al., 2017). The pathophysiological characteristics of PD can be 
reproduced both through exposure to neurotoxins and genetic manipulation. In fact, the non-
differentiated LUHMES can be easily transfected or infected with virus (Schildknecht et al., 2013; 
Stepkowski et al., 2015; Zhang et al., 2014; Höllerhage et al., 2017; Paiva et al., 2017). Several studies 
used these cell lines instead following treatment with neurotoxins, such as rotenone, 6-OHDA, MPP+ 
(Schildknecht et al., 2009; Stepkowski et al., 2015; Harris et al., 2018).  
The non-oncogenic human origin represents the main advantage of this cell line. However, these cells  
grow slowly, similarly to primary cells, and they need to have culture media supplemented with N2 
and fibroblast growth factor (FGF) (Scholz et al., 2011; Lopes et al., 2017). Recently, this cell line 
was used in 3D culture thus bypassing the problem to culture these cells for long-time period 
(Smirnova et al., 2016). Finally, the 3D LUHMES culture permits to investigate neurotoxic effects 
of different compounds and neurodegenerative processes (Harris et al., 2018).  
 
1.2.3 PC12 line 
PC12 is a cell line derived from a transplantable rat pheochromocytoma of the adrenal medulla. It 
can easily differentiate into neuronal-like cells through NGF induction when cultured on type IV 
collagen coated-coverslips (Greene and Tischler, 1976; Grau et al., 2012).  In this way, cells become 
able to release neurotransmitters from the vesicles, to develop axons and acquire electrical properties. 
PC12 contains DA and other catecholamines and can release NA following treatment with ascorbic 
acid. The treatment with NGF in combination with dexamethasone leads to increased vesicles and 
neurotransmitter release. Due to these features, PC12 cells have been used for the study of endocytosis 
through amperometry experiments (as reviewed by Westerink and Ewing, 2008). As described-above 
for the SH-SY5Y and the LUHMES cell lines, also the PC12 cells can be used as an in vitro model 
for PD through treatment with neurotoxins such as MPP+, 6-OHDA, and rotenone (Sai et al., 2008; 
Xu et al., 2017; Lee et al., 2018). They are also used for evaluation of a-synuclein pathological 
properties (Wang et al., 2017). Together with SH-SY5Y cell line, they represent the most used PD 
cellular model, but results obtained with these oncogenic cellular models must be taken with caution 
and evaluated in other cellular and animal models. 
 
1.2.4 MN9D line 
The MN9D cell line was obtained from the somatic fusion of mouse embryonic mesencephalic cells 
with neuroblastoma cells (N18TG2). One of the obtained clones, the MN9D, has the ability to 
synthesize catecholamines, express TH and generate sodium currents (Choi et al., 1991). In the 
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undifferentiated state, cells have a round cellular soma and have no process extension (Rick et al., 
2006). Treatment with GDNF and/or other factors (retinoic acid, Nurr1) leads to the arrest of the cell 
cycle, the formation of neurites and DA synthesis (Heller et al., 1996; Castro et al., 2001; Hermanson 
et al., 2003). Moreover, only through differentiation with GDNF followed by butyric acid (Rick et 
al., 2006), MN9D cells acquire electrophysiological properties comparable to the mature DA neurons. 
Similar to the other above-mentioned cell lines, MN9Ds are also used to investigate the role of a-
synuclein and undergo treatment with neurotoxins (Hussain et al., 1999; Wu et al., 2011; Spittau et 
al., 2012; Shao et al., 2015; Li et al., 2017). 
 
1.2.5 N27 line 
N27 cells were obtained from immortalized rat mesencephalic cells. These cells express low levels 
of TH and DA transporter (DAT), but are sensitive to 6-OHDA and to H2O2 (Clarkson et al., 1998). 
This cell-line has been used mainly in neurotoxicity, neurodegeneration studies and other cellular 
processes (Cantu et al., 2011; Dranka et al., 2012; Lopert et al., 2012; Cristòvao et al., 2013; Thomas 
et al., 2013; Harischandra et al., 2015). Recently, Gao and collaborators have recloned N27 cell lines, 
identifying a new clone with higher TH and DAT levels. Furthermore, these cells express VMAT and 
other transcription factors (NURR1, EN1, Fox42, PITX3) and release DA in normal and depolarizing 
conditions (Gao et al., 2016). 
 
1.2.6 Neuro 2a line  
Neuro 2a cells derive from mouse neural crest (Klebe et al., 1969) and present a neuronal and 
amoeboid morphology. Due to their characteristics these cells have been used in studies aimed at 
evaluating neuronal differentiation, axonal growth and signaling pathway neurotoxicity (Le Page et 
al., 2005; Salto et al., 2015). Moreover, they have been used to study Alzheimer's Disease (Kim et 
al., 2014). When differentiated, Neuro 2a cells express neuronal properties, such as the presence of 
neurofilaments, large amounts of microtubular proteins (Olmsted et al., 1970) and are easily 
transfected. Their peculiarity is the capability to differentiate into neurons in a very short time, 
through serum deprivation and/or modification of various culture medium factors (Lee and Nikodem, 
2004; Evangelopoulos et al., 2005; Wasilewska-Sampaio et al., 2005; Tremblay et al., 2010). 
Tremblay and collaborators (2010) showed that the use of dibutyryl cyclic adenosine monophosphate 
(dbcAMP) promotes Neuro 2a differentiation into DAergic cells, enhancing Nurr-related factor 1 
(Nurr1), TH and DA expression levels and thus being useful as PD model (Tremblay et al., 2010). 
 
1.3 Primary cultures 
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1.3.1 Primary DAergic cultures 
Even though different neurotransmitter systems are involved in PD, the hallmark of the disease is the 
degeneration of DAergic neurons of the substantia nigra pars compacta (SNpc) with a consequent 
reduction of DA levels in the striatum (Surmeier et al., 2017; Obeso et al., 2017). This leads to the 
appearance of the classical motor symptoms of the disease, namely resting tremors, bradykinesia and 
rigidity (Obeso et al., 2017). Accordingly, the setting up of reliable cell cultures of  
DAergic neurons provide a very useful in vitro model for the study of the molecular and cellular 
mechanisms involved in the neurodegeneration and for the understanding of the causes of selective 
neuronal vulnerability for this disorder (Studer, 2001).  
Early studies that used dissociated primary neuronal cultures obtained from rat SNpc showed the 
presence of about 40% DAergic neurons characterized by thick and straight primary processes 
dividing into several branches (Masuko et al., 1992). Physiological properties of these cultured 
DAergic neurons were similar to those reported for DAergic neurons in brain slices suggesting that 
it is possible to obtain dissociated cultures of the SN (Masuko et al., 1992). Results obtained by Kim 
and coworkers (1997) indicated that SN neurons of neonatal rats, after being dissociated, produce the 
same transmitters and the same receptors in culture as those in vivo.  
The method for culturing midbrain DAergic neurons from rat and mouse embryos has been optimized 
in several more recent studies (Weinert et al., 2015; Lopes et al., 2017) showing that this neuronal 
population undergoes to a rapid maturation and differentiation with the acquisition of synaptic, 
functional and morphological properties suitable for the analysis of molecular and cell biology events. 
Primary DAergic neurons have been widely used for evaluation of cell survival after treatment with 
neurotoxic compound possibly involved in PD pathogenesis or putative neuroprotective agents. 
Using cultured mouse mesencephalic neurons, an early study compared the toxicity of sequential 
exposure to rotenone (an inhibitor of mitochondrial complex I) and glutamate on GABAergic and 
DAergic neurons (Marey-Semper et al., 1995). This neuronal subtype was confirmed to be more 
vulnerable than inhibitory neurons to the toxic clues through a mechanism involving both NMDA 
receptor activation and a defective energy metabolism (Marey-Semper et al., 1995). More recently, 
the involvement of complex I inhibition in DAergic neuronal loss has been examined using a genetic 
mouse strain lacking Ndufs4 gene, encoding for a complex I essential subunit. Mesencephalic neurons 
in culture, however, did not show compromised survival despite lacking functionality of the complex 
(Choi et al., 2008). These results support the existence of other intrinsic properties that confer to 
DAergic neurons higher vulnerability to toxins like rotenone, paraquat and MPP+. Substance P, 
Neurokinins A/B, and Synthetic Tachykinin were shown to exert a selective neuroprotective action 
on mesencephalic DAergic neurons, highlighting the importance of excitatory inputs for survival of 
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this neuronal subtype (Salthun-Lassalle et al., 2005). A similar culture model in which DAergic 
neurons progressively die upon maturation was used to assess the mechanism of nicotine-mediated 
protection in PD. Interestingly, the beneficial effect occurred only in presence of simultaneous 
depolarizing stimuli able to elevate cytosolic calcium levels, through a mechanism involving a 
particular subtype of nicotinic acetylcholine receptors (Toulorge et al., 2011). 
The more recent development of PD-related transgenic mice has brought back a more extensive use 
of primary DAergic neurons prepared from these animal models. For instance, a work from Ramonet 
and collaborators in 2011 investigated the effects of two familiar PD mutations of LRRK2, R1441C 
and G2019S, in transgenic mouse models. Interestingly, cultures of midbrain DAergic neurons 
derived from G2019S-LRKK2 mice, which exhibit degeneration of the nigrostriatal pathway in vivo, 
were characterized by a considerable reduction of neurite length and complexity. (Ramonet et al., 
2011). A different approach, a binary tetracycline-dependent inducible gene expression system, was 
exploited to generate a transgenic mouse model expressing the mutated A53T α-syn in mDAergic 
neurons. Several neuronal abnormalities were found in vivo, including decreased DA release, Golgi-
apparatus fragmentation and impairment of the autophagy lysosomal pathway. Moreover, using 
midbrain cultures derived from transgenic mice, they reported an amelioration of α-syn-induced 
degeneration of mDAergic neurons by preventing proteasomal degradation of the transcription factor 
Nurr1 (Lin et al., 2012). 
 
1.3.2 Primary striatal neuronal cultures 
A well-known aspect of striatal anatomy and function is the presence of more than 95% spiny 
projection neurons (SPNs) in absence of a structured local excitation system. At dendritic spines of 
striatal SPNs, DAergic terminals from the substantia nigra pars compacta converge with 
glutamatergic terminals from the cerebral cortex. Molecular and functional interactions between these 
two neurotransmitter systems have been widely described (Gardoni and Bellone, 2015). The 
degeneration of the nigrostriatal DAergic pathway in PD leads to significant morphological and 
functional changes in the striatal neuronal circuitry, including modifications of the corticostriatal 
glutamatergic synaptic architecture with consequent loss of striatal synaptic plasticity (Calabresi et 
al., 2007). Overall, an integrated cross-talk between DA and glutamate systems plays an essential 
role in the regulation of a physiological motor behavior. Accordingly, early studies showed that when 
striatal neurons are grown alone in culture, they do not show a physiological spontaneous network 
activity and develop only a very low number of dendritic spines. However, primary neuronal striatal 
cultures have been widely used to investigate molecular mechanisms regulating DA and glutamate 
receptors and their signaling pathways at SPNs. Immunocytochemical and electrophysiological 
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characterization of cultured rat striatal neurons indicate that these cells have both DA D1 and D2 
receptors and NMDA-type glutamate receptors, abundant expression of main striatal markers such as 
calbindin, calretinin and the cannabinoid-1 receptor and voltage-gated K+ channel subunits 
characteristic of adult tissue (Falk et al., 2006; Hallett et al., 2006). In dissociated striatal neurons, 
DA or D1 receptor agonists potentiate NMDA receptor currents (Flores-Hernandez et al., 2002), with 
a mechanism involving the phosphorylation of the transcription factor Ca2+ and cyclic AMP response 
element binding protein (CREB) in the nucleus by means of NMDA receptor-mediated Ca2+ signaling 
(Dudman et al., 2003). Moreover, Hallett and colleagues (2006) observed a selective effect of DA D1 
receptor activation on the localization of NMDA subunits in striatal neurons.  
Growing of striatal neurons in presence of GFP-expressing cortical neurons leads to the appearance 
of spontaneous and evoked excitatory synaptic currents and a remarkable increase in the density of 
dendritic spines (Segal et al., 2003). Importantly, this event was strictly modulated by the application 
of tetrodotoxin (Segal et al., 2003). Fagni and collaborators further demonstrated the need of a cortical 
innervation for the correct development of striatal neurons in culture (Burguiere et al., 2013). They 
developed an in vitro model of mouse corticostriatal primary co-cultures, in which cortical neurons 
were isolated from embryonic wild-type mice and striatal neurons from embryonic mice expressing 
GFP. This allows the study of dendritic spine development and patch-clamp recording of the striatal 
neurons visualized by GFP fluorescence (Burguiere et al., 2013). Consistent with previous studies 
(Segal et al., 2003), striatal cells remained almost aspiny when cultured in the absence of cortical 
neurons. When cultured with cortical neurons, striatal neurons developed high density of dendritic 
spines (Burguiere et al., 2013). However, many of the above-mentioned approaches used for the study 
of cortical influences on striatal neurons have serious pitfalls. In particular, co-cultures of cortical and 
striatal neurons, although spontaneously active, are almost absent of cholinergic interneurons and 
develop connections from striatal cells to cortical cells that are not present in vivo, such as inhibitory 
striatocortical connections.  
To overcome some of these issues, more recently Garcia-Munoz and co-workers (2015) developed a 
method for growing cortical and striatal neurons in separated compartments that allows cortical 
neurons to innervate striatal cells in culture. The activity of both areas can be recorded in 
multielectrode arrays or individual patch recordings from pairs of cells. 
1.4 Human induced pluripotent stem cells 
The introduction of human induced pluripotent stem cells (iPSCs) technology, discovered by 
Yamanaka and Takahashi in 2006, revolutionized the modelling of human diseases. The possibility 
to reprogram fully differentiated cells from patients to the stemness and then redirecting them towards 
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the desired cell type brought a great power to biomedical research. This is particularly true for the in 
vitro modelling of physiology and pathophysiology of the central nervous system including the field 
of neurodegenerative disorders, previously restrained by the impossibility to obtain affected tissues 
and cells directly from patients. Therefore, iPSCs allow to overcome some of the obstacles, given 
either by the use of animal models, such as species-specificity of cellular pathways, ethical issues and 
the limited availability of post-mortem human brain tissue. More in detail,  iPSCs give the opportunity 
to have disease-relevant neuronal subtypes that retain the specific genetic background of the patient. 
Taking into account the specific genetic settings of an individual, the development of a personalized 
drug treatment is a fundamental requirement and a highly relevant topic in high throughput drug 
screening (Haston and Finkbeiner, 2016). 
In this framework, the combination of iPSC technology and very recent genome editing techniques 
(Mali et al., 2013) allows to generate isogenic control cells that maintain the same genetic background 
of the patient leading to a great advantage in the modelling of complex brain disorders such as PD.  
 
1.4.1 Modelling genetic PD with iPSCs 
Aberrations in SNCA gene, coding for the protein a-synuclein, are one of the most common defect 
causing familiar autosomal dominant Parkinson’s disease. Devine and collaborators (2011) 
successfully differentiated a subset of iPSCs lines from patients bearing multiplication of SNCA locus 
into midbrain DAergic neurons (mDA). Genomic DNA analyses confirmed the alteration of SNCA 
to be still present in iPSC lines. In addition, mDA neurons differentiated from mutated iPSCs 
demonstrated to have a double quantity of the protein with respect to healthy relative-derived neurons 
(Devine et al., 2011). 
The work of Byers and collaborators in the same year (2011) also reported accumulation of α-
synuclein in DA neurons from a PD patient bearing SNCA triplication. Aberrant levels of α-synuclein 
were not the only disease feature exhibited by PD neurons, which also showed increased sensitivity 
to oxidative stress, caused by exposure to hydrogen peroxide, together with augmented oxidative 
stress markers (Byers et al., 2011). 
Soldner and co-workers (2011) used for the first time iPSCs technology combined to genome editing 
in the field of PD research. Exploiting Zinc-finger nuclease (ZFN)-mediated genome editing they 
generated a set of isogenic disease and control human iPSCs by correcting two point mutations in the 
α-synuclein gene. Specifically, they either derived hiPSCs from a patient carrying the A53T (G209) 
α-synuclein mutation followed by the correction of this mutation or, alternatively, by generating 
either the A53T (G209A) or E46K (G188A) mutation in the genome of wild-type hESCs. They 
showed that patient-derived hiPSCs upon targeted gene correction of the A53T mutation were still 
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able to differentiate into tyrosine hydroxilase-expressing DA neurons, lacking the expression of the 
mutated A53T/G209A transcript.  
In the same year, Nguyen and collaborators (2011) reported the generation of iPSC lines from PD 
patients harbouring the LRRK2 G2019S mutation. Midbrain DAergic neurons (mDA) derived from 
iPSC lines exhibited cardinal PD features as accumulation of α-synuclein, upregulation of oxidative 
stress response genes and increased susceptibility to neurotoxins (Nguyen et al., 2011). Increased α-
synuclein levels accompanied by alterations of autophagy were also reported by another study in 
mDA neurons differentiated from iPSCs lines harbouring the same LRRK2 G2019S mutation 
(Sánchez-Danés et al., 2012). Interestingly, they found the same pathogenic features also in mDA 
neurons from idiopathic PD patients (Sánchez-Danés et al., 2012). Moreover, besides accumulation 
of autophagic vacuoles, both sporadic PD and LRRK2-mutated mDA neurons were characterized by 
decreased number of neurites and aberrant neurite arborization with respect to neurons derived from 
age and sex matched healthy controls.  However, polymorphisms in other genes involved in PD 
pathogenesis, as SNCA or MAPT, give a large contribution in affecting phenotypes of individuals 
with familiar LRRK2-PD.  This genetic variability makes the study of the effect of the specific 
mutation more complex (Botta-Orfila et al., 2012; Golub et al., 2009). However, the use of isogenic 
gene correction in iPSCs from patients can help to overcome this issue. Reinhardt and collaborators 
(2013a) used this tool to analyse the molecular alterations conferred by the G2019S LRRK2 lesion 
in mDA neurons differentiated from isogenic iPSC lines. The targeted gene correction was shown to 
rescue PD-associated phenotypes, including neurite shortening and basal autophagy defects.  
Experimental modelling of PINK1 and PARK2-dependent PD has always been complex. In vivo, 
knockout of the two genes in mouse models do not lead to degeneration of nigral DA neurons 
(Dawson et al., 2010). Issues in reproducing disease phenotype are not shown solely by in vivo 
models. Recent studies on iPSC derived DA neurons reported that loss of function mutations in both 
the two genes are not sufficient to induce cell death in culture if not exposed to external clues (Miller 
et al., 2013; Chang et al., 2016). To note, the majority of studies examining PINK1-associated PD 
has been usually performed by means of knockdown strategies and models with limited relevance for 
human pathophysiology. A contribution to dissect the role of PINK1 mutations using iPSC 
technology was given by a work from Seibler (2011). Skin fibroblasts taken from three patients 
harbouring different missense and nonsense PINK1 mutations - nonsense (c.1366C>T; p.Q456X) and 
missense (c.509T>G; p.V170G) - were reprogrammed to iPSCs and then directed to DA neurons. 
Several defects became apparent after mitochondrial depolarization, most importantly the defective 
recruitment of the exogenously expressed Parkin to mitochondria. Moreover, neurons were 
characterized by increased mitochondrial copy number coupled to upregulation of the mitochondrial 
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biogenesis regulator PGC-1α, all defects rescued by wild-type PINK1 expression (Seibler et al., 
2011). 
iPSC technology has proven to be useful also to dissect convergent disease mechanisms shared 
between different familiar PD forms. Cooper and co-workers (2012) generated neural cells from 
iPSCs of PD patients or pre-symptomatic subjects mutated in PINK1 and LRRK2 genes. Compared 
to neurons derived from healthy individuals, these cells had several alterations in the mitochondrial 
response that could be rescued by coenzyme Q10, rapamycin or by an inhibitor of LRRK2 kinase 
activity.  
The G2019S LRRK2 mutation was shown to delay the arrest of damaged mitochondria and thus to 
slow mitophagy initiation in iPSC derived neurons (Hsieh et al., 2016). The analysis revealed that the 
pathways of LRRK2 and PINK1/Parkin works in parallel, converging on the mitochondrial protein 
Miro. To note, dysregulation of the same process and aberrant mitochondrial motility were found also 
in sporadic PD patients-derived cell lines (Hsieh et al., 2016). 
A very recent study by di Domenico and coworkers (2019) contributed to analyse astrocyte-neuron 
interplay in PD pathogenesis, already described to be involved in mechanisms of α-synuclein 
spreading and degradation. (Braak 2007; Lee et al., 2010; Loria et al., 2017). Co-cultures experiments 
were set up deriving ventral mDA (vmDA) neurons and astrocytes from iPSC of PD patients carrying 
the LRRK2 G2019S mutation and healthy controls. Co-culturing healthy vmDA neurons with PD 
patients-derived astrocytes was sufficient to reduce neuron number and increase a-synuclein levels. 
On the other hand, neurodegenerative signs of PD vmDA neurons were ameliorated by co-culturing 
them with healthy astrocytes. More in detail, PD derived astrocytes were characterized by a 
progressive α-synuclein accumulation along days in culture, probably due to altered proteostasis of 
this protein and alteration of the autophagy flux (di Domenico et al., 2019). 
 
 
1.4.2 Modelling sporadic PD with iPSCs 
iPSC neurons derived from familiar PD patients with known genetic lesions have provided clues 
about the molecular aspects of DAergic degeneration. However, up to now data on iPSCs neurons 
derived from sporadic PD patients are less available with respect to hereditary forms, mostly due to 
the difficulty of deriving neurons from large cohort of idiopathic PD patients.  
Epigenomic alterations are common events in both sporadic PD patients and those with a monogenic 
hereditary form of the disease. The work of Santiago and collaborators (2015) reported for the first 
time that iPSC-derived DAergic neurons from sporadic and LRRK2-associated PD patients share the 
same epigenomic changes compared to healthy individuals. Interestingly, these methylation 
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abnormalities become apparent only upon differentiation into DAergic neurons but not in other 
neuronal types, as well as they are lacking in somatic parental cells or undifferentiated iPSCs. 
A recent work conducted an extensive transcriptomic and epigenomic study on fibroblast, iPSCs and 
sporadic PD-derived neuronal cells. In the latter, pathways involved in PD pathogenesis, such as 
CREB and PGC1α-regulating pathway, showed alterations in gene expression. Moreover, they also 
found a differential regulation of miRNA and piRNA molecules between control and PD-patients, 
both in cells and post-mortem tissue samples. The derivation of neurons from idiopathic PD patients 
can thus provide relevant data about the epigenetic signature of sporadic PD, to identify possible 
novel pathogenetic pathways (Schulze et al., 2018). 
Genome editing in hiPSC can provide insights into novel associated risk variants in complex 
neurodegenerative disorders, functionally connecting these variations to a phenotype. A novel 
strategy was used by Soldner and collaborators in 2016 to unravel the transcriptional effects of 
variants in non-coding regulatory elements, by specifically tuning the genetic settings of the 
experimental system. A novel common risk variant in a distal enhancer that regulates SNCA 
expression was found to be associated to PD development. Moreover, as a genetic mechanism 
responsible for the altered SNCA expression, it was identified an aberrant binding to their target 
sequences of EMX2 and NKX6-1, two transcription factors specific of the brain (Soldner et al., 2016). 
Increasing evidence reports a relevant role of non-cell autonomous component in PD, which seems 
to modulate disease progression and spreading.  
 
1.4.3 iPSCs in drug screening 
Besides the new possibilities iPSCs introduced for human disease modelling, their intrinsic features 
could also improve drug screening and identification of new therapeutic targets. Stem cell technology 
combined to development of high through-put screening (HTS) and high-content screening platforms 
(HCS) can circumvent the issues intrinsic to these assays. More specifically, these platforms screen 
billions of compounds measuring parametric outputs from an incredibly high number of wells, 
making the reproducibility of the assay one of the fundamental features to get consistent results. 
However, statistical significance in these types of assays is usually not so easy to obtain, considering 
the high variability of stem cell cultures. Reinhardt and collaborators (2013b) described the derivation 
and propagation of human neural progenitor cells (smNPCs) by means of only small molecules for 
self-renewal and expansion, thus significantly reducing time-consuming steps of selection, manual 
handling and the related costs. smNPCs demonstrates their ability to be efficiently directed towards 
central nervous system and neural crest lineages, as well as a robust capability of immortal expansion. 
Moreover, after two weeks of maturation mDA neurons derived from smNPCs resulted to be 
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electrophysiologically active and able to form integrate synaptic connections. smNPCs-derived 
neurons demonstrated to recapitulate neurodegenerative signs of the LRKK2 G2019S mutation. Upon 
exposure to oxidative cues, mDA neurons from patients exhibited a disease phenotype overlapping 
to the one already described by a previous study (Nguyen et al., 2011). Compared to the other cell 
types used in HTS analyses, smNPCs- derived neurons represent a more affordable tool to be used in 
screening of neuroprotective compounds. (Reinhardt et al., 2013b). 
Concerning phenotypic-based drug screening, iPSCs derived neurons were used to assess the efficacy 
of small molecules inhibiting α-synuclein toxicity previously identified through a yeast screening. In 
particular, cortical neurons were derived from familiar PD patients bearing the A53T mutation in 
SNCA, known to have a high probability to develop cortical α-synuclein pathology and PD dementia. 
Two compounds identified to suppress α-synuclein toxicity in yeast were then tested in human 
cortical neurons. The N-arylbenzimidazole NAB2, acting through the Rsp5-Nedd4 pathway, was 
demonstrated to revert some of the pathologic phenotypes of PD neurons (as increased NO levels and 
immature forms of glucocerebrosidase and nicastrin proetins), found also in A53T-mutated patient 
cortices (Chung et al., 2013). 
One of the drawbacks of iPSCs’ disease modelling is represented by a heterogenous and not always 
consistent appearance of the disease phenotypes from line to line. Taking advantage of this issue, a 
recent study applied both bulk and high-resolution single cell transcriptomics in order to decipher 
gene expression changes driven by the N370S variant in glucocerebrosidase gene (GBA). 
Heterozygous mutations in GBA were demonstrated to be the most common genetic risk factor for 
PD (Sidransky et al., 2009), carried by about 5-10% of patients. Individuals harbouring the most 
common GBA mutation (N370S) have a clinical presentation typical of idiopathic PD forms (Beavan 
and Schapira, 2013). Transcriptomic analyses of DA neurons differentiated from PD-GBA patients 
revealed a deregulated axis, triggered by nuclear mislocalization of HDAC4, that progressively leads 
to endoplasmic reticulum stress. DA neurons were then used to test different pharmacological 
compounds able to modulate localization and activity of HDAC4. Repurposed drugs, already in 
clinical trial setting for various types of cancer, were tested in diseased neurons for their ability to 
modulate localization and activity of HDAC4. This regulation proved to be efficacious in rescuing 
most of the cellular abnormalities of GBA-PD neurons, highlighting HDAC4 as a possible novel 
target in PD treatment. Moreover, since single cell RNA-sequencing can harness inter-neuronal 
variability, transcriptomic analyses built a stratification of patients harbouring GBA N370S mutation 




A key progress in the last five years has not only been the generation of DAergic neurons from human 
induced pluripotent stem cells (Grealish et al., 2014) but also the development of a valid method for 
their differentiation into large multicellular organoid-like structures expressing characteristic markers 
of human midbrain. Lancaster and collaborators (2013) reported for the first time the generation of a 
three-dimensional cerebral organoid derived from pluripotent stem cells. The key step of their 
protocol, which was modified from neural rosettes derivation technique, is the neural induction of 
embryoid bodies kept in suspension and in agitating conditions. Without the use of patterning growth 
factors, cerebral organoids are allowed to self-organize in discrete identities, resembling human brain 
early development (Lancaster et al., 2013, Lancaster and Knoblich, 2014). In the last few years, 
different modifications have been implemented to the protocol, mostly to reach an increased neuronal 
survival, oxygen supply and axon outgrowth. The overall improvement of these systems allows a 
more accurate modelling of neuronal circuitry and physiological brain organization. An interesting 
approach derived from organotypic slice culture method has been applied to the technique. Air–liquid 
interface cerebral organoids are characterized by a more physiological morphology and significantly 
improved survival, together with an axon outgrowth dynamic similar to the one found in vivo 
(Giandomenico et al., 2019). Jo and coworkers (2016) produced human 3D midbrain-like organoids 
containing electrically active and functionally mature midbrain DAergic neurons and with detectable 
DA production. These midbrain-like organoids also produced neuromelanin-like granules that were 
comparable to those characterized from human substantia nigra. Notably, few years ago different 
groups published the use of 3D brain organoids as model for pathological human phenotype, 
including neurodegenerative diseases such as Alzheimer’s disease (Raja et al., 2016; Pavoni et al., 
2018) Accordingly, the rapid advancement of this approach offers the possibility of a key progress in 
the evaluation of therapeutic approaches on more physiologically relevant models opening new 
perspectives also for future approaches in drug discovery.  
A very recent study described the generation of isogenic iPSC-derived midbrain organoids containing 
a G2019S mutation in LRRK2 (Kim et al., 2019). 3D midbrain organoids show in a differentiation-
dependent manner the expression of several DAergic neuronal markers such as VMAT2, TH, NURR1 
and DAT as well as the expression of additional midbrain markers suggesting that these organoids 
from day 45 closely resemble the mature DAergic midbrain (Kim et al., 2019). Of relevance, the 
study showed that LRRK2-mutant midbrain organoids are characterized by i. pathological signatures 
detected in LRRK2 PD patients, such as augmented aggregation and aberrant clearance of a-
synuclein and ii. gene expression profiles mimicking those observed in mutant LRRK2-associated 
sporadic PD patients (Kim et al., 2019). Overall, this study suggests that midbrain 3D organoids can 




PD is mainly characterized by the degeneration of nigrostriatal DAergic neurons leading to the onset 
of motor symptoms of the disorder in patients. The use of a large number of in vitro experimental 
models provided the identification of several cellular and molecular mechanisms involved in PD 
pathogenesis. Overall, these models gave a great contribution to PD research in the last decades. 
However, as described also above, all available in vitro models have many disadvantages and 
currently, a reliable and optimal in vitro model for the understanding of all aspects of PD etiology is 
still lacking (see table 1). 
Of key relevance, the recent development of iPSC and organoids technology has allowed the setting 
up of in vitro models of midbrain DAergic neurons using cells derived from PD patients. In particular, 
novel differentiation protocols for both iPSC and organoids have clearly demonstrated that these in 
vitro models have all molecular, functional, maturation and morphological features to be used for the 
study of neurodegenerative diseases such as PD. Accordingly, these human-derived models open new 
routes for PD modeling and drug screening that can be further developed and optimized in the next 
few years.  
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Table 1 - List of the main advantages and disadvantages of the in vitro models used in the field of PD. 
 
Model Advantages Disadvantages 
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Cell lines 
- high reproducibility  
- easy transfection and genetic manipulation 
- expression of the DAergic machinery upon 
differentiation 
- human genetic background 
- oncogenic (presence of chromosomal 
and genomic aberrations) 
- absence of several key neuronal 
functional properties 




- physiological properties similar to in vivo 
DAergic neurons  
- rapid maturation and differentiation  
- possibility to derive neurons from genetic 
animal models 
- heterogeneous system, low 
reproducibility  
- high percentage of glial cells 





- high expression of DA receptors, NMDA-
type glutamate receptors and of the main 
striatal markers 
- possibility of co-colturing with cortical 
neurons  
- heterogeneous system, low 
reproducibility  
- absence of spontaneous network 
activity and almost aspiny 
 
iPSCs 
- mature neuronal physiology and 
morphology  
- human genetic background 
- possibility to derive cells from PD patients 
and to generate isogenic controls 
 
- technical difficulties, time consuming  
- issues regarding loss of epigenetic 
influence during reprogramming  




- overcoming of simplified 2D models 
- presence of glia-neurons interactions  
- possibility to recapitulate cell autonomous 
and non-cell autonomous aspects  
- exhibit key features of mature midbrain 
DAergic neurons  
- patients’ specific model 
- rise of ethical issues 
- highly expensive systems  
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Model Advantages Disadvantages 
Cell lines 
- high reproducibility  
- easy transfection and genetic manipulation 
- expression of the DAergic machinery upon 
differentiation 
- human genetic background 
- oncogenic (presence of chromosomal 
and genomic aberrations) 
- absence of several key neuronal 
functional properties 




- physiological properties similar to in vivo 
DAergic neurons  
- rapid maturation and differentiation  
- possibility to derive neurons from genetic 
animal models 
- heterogeneous system, low 
reproducibility  
- high percentage of glial cells 





- high expression of DA receptors, NMDA-
type glutamate receptors and of the main 
striatal markers 
- possibility of co-colturing with cortical 
neurons  
- heterogeneous system, low 
reproducibility  
- absence of spontaneous network 
activity and almost aspiny 
 
iPSCs 
- mature neuronal physiology and 
morphology  
- human genetic background 
- possibility to derive cells from PD patients 
and to generate isogenic controls 
 
- technical difficulties, time consuming  
- issues regarding loss of epigenetic 
influence during reprogramming  




- overcoming of simplified 2D models 
- presence of glia-neurons interactions  
- possibility to recapitulate cell autonomous 
and non-cell autonomous aspects  
- exhibit key features of mature midbrain 
DAergic neurons  
- patients’ specific model 
- rise of ethical issues 
- highly expensive systems  
- time consuming and several technical 
challenges 
 
Table 1: List of the main advantages and disadvantages of the in vitro models used in the field of PD. 
 
